Abstract:Abstract 5047 Purpose Patients older than 60 years with acute myeloid leukemia (AML) or with chronic myeloid leukemia in blast phase (CML-BC) or myelodysplastic syndrome (MDS) have non-intensive treatment options because of the lack of effectiveness and the toxicity of available therapies. We investigated the efficacy and toxicity of the low-dose cytarabine and aclarubicin in combination with hypomethylating agent decitabine and granulocyte colony-stimulating factor priming as induction therapy in MDS, CML-BC and older patients with AML. Patients and Methods We described 28 consecutive patients (median age 65.5 years, range 49–78 years with MDS (n= 7) or AML (n= 17), or CML-BC (n=4). Among them, Seventeen were cases of AML (10 previously untreated AML, 3 bone marrow relapse, 2 extramedullary relapse and 1 MDS-AML); 4 were cases of CML-BC who were resistant to imatinib or nilotinib therapy and 7 were cases of MDS. Cytogenetic analysis was performed in all the patients, showing 7 patients had cytogenetic aberrations. All patients were treated with decitabine 15 mg/m2 intravenously for 5 consecutive days (d1-5) in combination with cytarabine 10 mg/m2 q12h for 7 days (d3-9) and aclarubicin 10mg every day for 4 days (d3-6) and granulocyte colony-stimulating factor (G-CSF) 300μg every day (d 0–9) priming (D-CAG). G-CSF was withdrawn when the white blood cell count (WBC) >20×109/L. Hydroxyurea or in combination with homoharringtonine 1mg/d intravenously was treated until WBC was Results Fifteen older patients with AML (median 68 years, range 60–78 years) were enrolled. Among those patients, 10 were in previously untreated AML, 3 bone marrow relapse, 1 extramedullary relapse and 1 secondary AML. The overall response rate (ORR) was 86.7% (13/15) in all older patients, 80.0% (8/10) in patients with previously untreated AML, and the complete rate (CR) was 73.3% after one cycle. 3 older patients with bone marrow relapse achieved. Two patients with extramedullary relapse achieved partial remission (PR) after one cycle. Two fourth of patients with high WBC more than 100×109/L at the time of diagnosis achieved CR. 7 patients with MDS (6 high-risk MDS, 1 RCMD) achieved the therapy. 3/5 patients achieved the CR or 2/5 PR. Other 2 high-risk MDS patients with refractory to convenient regimens such as CAG and HA had non-response to D-CAG regimen. All of the CML-BC patients received the one cycle of D-CAG regimen. Three fourth CML-BC patients achieved the CR and one stopped disease progression. All patients completed the treatment and there was no induction mortality. Grade 4 neutropenia and thrombocytopenia was universal. Median duration of granulocyte recovery (0.5×109/L) was 13 days(4–20), and that of platelet recovery (×109/L) was 10 days(2–16).The platelets rose above 600×109/L in 5 patients and all counts returned to the normal range with a week and there were no thrombotic complications including one patient with atrial fibrillation. The most common toxicities were myelosuppression, febrile neutropenia. Conclusion D-CAG regimen as the induction therapy seemed to be a safe and effective regimen for patients with untreated/relapsed AML, MDS and CML-BC, including older patients, and it has well tolerance. Disclosures: No relevant conflicts of interest to declare.

Effect of CAG induction therapy in patients with acute myeloid leukemia

Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.

Aclarubicin and Low-Dose Cytosine Arabinoside in Combination with Granulocyte Colony-Stimulating Factor in Treating Acute Myeloid Leukemia Patients with Relapsed or Refractory Disease and Myelodysplastic Syndrome: a Multicenter Study of 112 Chinese Patients.

CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease

Curative Effect of CAG Regimen on Patients with Untreated Acute Myeloid Leukemia and Its Mechanism

CAG Regimen for Refractory or Relapsed Adult T-Cell Acute Lymphoblastic Leukemia: A Retrospective, Multicenter, Cohort Study

A Meta-Analysis of CAG (cytarabine, Aclarubicin, G-CSF) Regimen for the Treatment of 1045 Patients with Leukemia in China and Japan,

A Meta-Analysis of CAG (cytarabine, Aclarubicin, G-CSF) Regimen for the Treatment of 1029 Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Effect of Low-Dose Cytarabine and Aclarubicin in Combination with Decitabine and Granulocyte Colony-Stimulating Factor Priming on the Outcome of Patients with Myeloid Neoplasms

Modified Cladribine, Cytarabine, and G-CSF As a Salvage Regimen in Patients with Relapsed/refractory Acute Myeloid Leukemia: a Bridge to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation

[The Efficacy and Safety of HAA Regimen As Induction Chemotherapy in 150 Newly Diagnosed Acute Myeloid Leukemia].

A single center cross-sectional study on the efficacy of low-dose cytarabine and aclramycin combined with granulocyte colony-stimulating factor (CAG regimen) in elder adults with acute myeloid leukemia

Autophagy Induction of Acute Myeloid Leukemia (aml) Cells after Treatment with Low Dose-Cytarabine (Ara-C) and Enhanced Cytocidal Effect on Aml Cells by Combined Treatment with Ara-C Plus Lenograstim.

Observations of Efficacy of CAG Regimen in Treatment of Relapsing, Refractory and Secondary Acute Myeloid Leukemia

Cytarabine, Aclarubicin and Granulocyte Colony-Stimulating Factor Regimen Represents an Effective and Safe Salvage Regimen for Patients with Acute Myeloid Leukemia Refractory to First Course of Induction Chemotherapy

Outcomes and Survival Analysis of Patients with AML and High Risk MDS Treated by CAG Regimen

Effect of Low-Dose Cytarabine, Homoharringtonine and Granulocyte Colony-Stimulating Factor Priming Regimen on Patients with Advanced Myelodysplastic Syndrome or Acute Myeloid Leukemia Transformed from Myelodysplastic Syndrome.

The clinical curative effect observation of patients with acute leukemia and high risk MDS treated by CAG regimen

Clinical Study of CAG Regimen in Treating Acute Myeloid Leukemia

Combination Chemotherapy with Low‐dose Cytarabine, Homoharringtonine, and Granulocyte Colony‐stimulating Factor Priming in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Efficacy and Safety of Decitabine in Combination with G-CSF, Low-Dose Cytarabine and Aclarubicin in MDS-EB and AML-MRC